{
    "organizations": [],
    "uuid": "a62cd6ed3fbc746e2e5dd2fbd33524091ad0f238",
    "author": "",
    "url": "https://www.reuters.com/article/brief-veru-to-present-at-2018-genitourin/brief-veru-to-present-at-2018-genitourinary-cancers-symposium-idUSFWN1PW0O4",
    "ord_in_thread": 0,
    "title": "BRIEF-Veru to Present At 2018 Genitourinary Cancers Symposium",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 6 (Reuters) - Veru Inc:\n* VERU ANNOUNCES PRESENTATION OF DATA DEMONSTRATING EFFICACY OF VERU-111 IN A TAXANE RESISTANT HUMAN PROSTATE CANCER MODEL AT THE 2018 GENITOURINARY CANCERS SYMPOSIUM\n* VERU INC - ‍IN EARLY TOXICITY STUDIES, VERU-111 WAS WELL TOLERATED​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-06T15:36:00.000+02:00",
    "crawled": "2018-02-06T15:47:23.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "veru",
        "inc",
        "veru",
        "announces",
        "presentation",
        "data",
        "demonstrating",
        "efficacy",
        "taxane",
        "resistant",
        "human",
        "prostate",
        "cancer",
        "model",
        "genitourinary",
        "cancer",
        "symposium",
        "veru",
        "inc",
        "early",
        "toxicity",
        "study",
        "well",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}